Kornitzer Capital Management Inc. KS trimmed its holdings in shares of Natera Inc (NASDAQ:NTRA) by 19.1% in the third quarter, according to its most recent filing with the SEC. The firm owned 412,649 shares of the medical research company’s stock after selling 97,737 shares during the period. Kornitzer Capital Management Inc. KS owned approximately 0.59% of Natera worth $13,535,000 as of its most recent filing with the SEC.
Several other large investors have also added to or reduced their stakes in NTRA. Vanguard Group Inc. lifted its position in Natera by 17.4% during the second quarter. Vanguard Group Inc. now owns 5,604,296 shares of the medical research company’s stock worth $154,567,000 after purchasing an additional 832,187 shares during the period. BlackRock Inc. increased its holdings in Natera by 74.4% in the 2nd quarter. BlackRock Inc. now owns 4,842,318 shares of the medical research company’s stock worth $133,552,000 after acquiring an additional 2,065,977 shares during the last quarter. Jennison Associates LLC increased its holdings in Natera by 24.4% in the 2nd quarter. Jennison Associates LLC now owns 4,434,727 shares of the medical research company’s stock worth $122,310,000 after acquiring an additional 869,420 shares during the last quarter. Orbimed Advisors LLC increased its holdings in Natera by 199.2% in the 2nd quarter. Orbimed Advisors LLC now owns 3,224,328 shares of the medical research company’s stock worth $88,927,000 after acquiring an additional 2,146,742 shares during the last quarter. Finally, Macquarie Group Ltd. increased its holdings in Natera by 1.7% in the 2nd quarter. Macquarie Group Ltd. now owns 2,262,808 shares of the medical research company’s stock worth $62,408,000 after acquiring an additional 36,939 shares during the last quarter. 95.52% of the stock is owned by institutional investors.
In related news, CTO Jonathan Sheena sold 1,033 shares of the business’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $29.50, for a total transaction of $30,473.50. Following the transaction, the chief technology officer now directly owns 241,937 shares in the company, valued at approximately $7,137,141.50. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Michael Burkes Brophy sold 2,859 shares of the business’s stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $38.25, for a total value of $109,356.75. Following the transaction, the chief financial officer now owns 16,630 shares in the company, valued at $636,097.50. The disclosure for this sale can be found here. Insiders have sold 64,557 shares of company stock valued at $2,241,958 in the last quarter. 9.29% of the stock is currently owned by company insiders.
Natera stock traded up $1.07 during mid-day trading on Friday, hitting $36.93. The company had a trading volume of 44,283 shares, compared to its average volume of 781,046. The company has a current ratio of 2.54, a quick ratio of 2.42 and a debt-to-equity ratio of 1.10. The stock’s 50 day moving average price is $36.27 and its two-hundred day moving average price is $28.57. Natera Inc has a 12 month low of $11.08 and a 12 month high of $40.92. The company has a market capitalization of $2.61 billion, a PE ratio of -17.22 and a beta of 1.45.
Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Wednesday, November 6th. The medical research company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.20. Natera had a negative return on equity of 273.92% and a negative net margin of 46.78%. The firm had revenue of $77.90 million for the quarter, compared to the consensus estimate of $73.97 million. During the same period in the prior year, the company posted ($0.49) earnings per share. The company’s quarterly revenue was up 19.3% on a year-over-year basis. Equities research analysts anticipate that Natera Inc will post -2.06 EPS for the current year.
A number of brokerages have recently issued reports on NTRA. Cowen lifted their price target on Natera from $30.00 to $42.00 and gave the company an “average” rating in a research report on Friday, October 18th. Canaccord Genuity reiterated a “buy” rating and set a $44.00 price target on shares of Natera in a research report on Wednesday, October 16th. ValuEngine upgraded Natera from a “hold” rating to a “buy” rating in a research report on Friday, November 1st. Craig Hallum lifted their price target on Natera from $37.00 to $49.00 and gave the company a “buy” rating in a research report on Thursday. Finally, BidaskClub upgraded Natera from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, October 8th. Two analysts have rated the stock with a hold rating, four have assigned a buy rating and two have assigned a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $42.50.
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Recommended Story: Options Trading – What is a Straddle?
Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera Inc (NASDAQ:NTRA).
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.